Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
The FDA has expanded approval of the PARP inhibitor talazoparib (Talzenna) combined with enzalutamide (Xtandi) to treat patients with hormone-sensitive metastatic prostate cancer harboring HRR gene mutations — an earlier line than its previous 2023 indication. The phase 3 TALAPRO-3 trial showed the combo cut the risk of radiographic progression or death by 52% compared to enzalutamide alone, with median progression-free survival not yet reached in the treatment arm.
The FDA has expanded the approved indication for talazoparib (Talzenna) plus enzalutamide (Xtandi) to include patients with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer with homologous recombination repair (HRR) gene mutations. Previously approved in 2023 for metastatic castration-resistant prostate cancer, this expansion moves the combination into an earlier treatment setting — potentially reaching patients before disease becomes more resistant and harder to treat.
The decision was backed by the phase 3 TALAPRO-3 trial, which enrolled 599 patients with HRR gene-mutated mAPMN/S prostate cancer. All participants received androgen deprivation therapy, with half also getting talazoparib and the other half a placebo, both alongside enzalutamide. Clinical benefits were consistent across patients with BRCA and non-BRCA HRR mutations, underscoring the importance of biomarker testing at diagnosis.
By the Numbers:
Why it matters: Moving this effective combination earlier in the treatment journey could delay disease progression at a stage when patients may benefit most — and the consistent results across BRCA and non-BRCA mutations broaden its potential reach significantly.
